Skip to content
DataLookout
Menu

VitaliThyNCT07570316

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

StatusRecruiting
PhasePhase 3
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 32 → 35 locations
  2. Minor Trial sites expanded: 26 → 32 locations
  3. Minor Trial sites expanded: 23 → 26 locations
    • Site details revised at 4 of 26 sites
  4. Minor Study sites: 23 to 26
  5. Notable Eligibility criteria expanded, about 9 words
    • Study sites: 22 to 23
    • Secondary endpoints: details revised at 4 of 20 entries
  6. Minor Trial sites expanded: 18 → 22 locationsv3
  7. Notable Recruitment opened
    • Trial sites expanded: 0 → 18 locations
    • Start date changed from estimate of Jun 2026 to Jun 10, 2026
    v2
  8. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Timeframe: Up to 24 weeks (part A)

Secondary (20)

Time to becoming euthyroid off ATDs in part A
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Time to becoming euthyroid off ATDs and TRAb seronegative
Show 15 moreShow less
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Time to becoming euthyroid
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Percentage of participants who remain euthyroid without ATDs
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Incidence of AEs and SAEs
Change in ThyPRO-39 over time
Change in PROMIS-PF10a over time
Efgartigimod serum concentrations over time
Percentage change from baseline in total IgG levels in serum over time
Percentage change from baseline in TRAb serum levels over time
Incidence of ADA against efgartigimod in serum
Incidence of antibodies against rHuPH20 in plasma
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

Arms and interventions

Part A - efgartigimod PH20 SC PFSExperimental

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

Part A - placebo PH20 SC PFSPlacebo comparator

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

Part B - efgartigimod PH20 SC PFSExperimental

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

Part B - placebo PH20 SC PFSExperimental

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

Part C - efgartigimod PH20 SC PFSExperimental

Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Biologicals: Efgartigimod PH20 SC

Other: Placebo PH20 SC

Sites

35 sites in 3 countries

United States 29, Georgia 5, United Kingdom 1